- Home
- WYHG vs ATAI Comparison
WYHG vs ATAI Comparison
Compare WYHG & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WYHG
- ATAI
- Stock Information
- Founded
- WYHG 1915
- ATAI 2018
- Country
- WYHG China
- ATAI Germany
- Employees
- WYHG 491
- ATAI N/A
- Industry
- WYHG
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- WYHG
- ATAI Health Care
- Exchange
- WYHG NYSE
- ATAI Nasdaq
- Market Cap
- WYHG 261.7M
- ATAI 293.5M
- IPO Year
- WYHG 2024
- ATAI 2021
- Fundamental
- Price
- WYHG $9.38
- ATAI $1.31
- Analyst Decision
- WYHG
- ATAI Strong Buy
- Analyst Count
- WYHG 0
- ATAI 4
- Target Price
- WYHG N/A
- ATAI $9.00
- AVG Volume (30 Days)
- WYHG 353.7K
- ATAI 1.8M
- Earning Date
- WYHG 01-01-0001
- ATAI 05-14-2025
- Dividend Yield
- WYHG N/A
- ATAI N/A
- EPS Growth
- WYHG 10.09
- ATAI N/A
- EPS
- WYHG 0.27
- ATAI N/A
- Revenue
- WYHG $144,231,605.00
- ATAI $308,000.00
- Revenue This Year
- WYHG N/A
- ATAI $65.58
- Revenue Next Year
- WYHG N/A
- ATAI N/A
- P/E Ratio
- WYHG $5.05
- ATAI N/A
- Revenue Growth
- WYHG 9.73
- ATAI N/A
- 52 Week Low
- WYHG $3.55
- ATAI $1.03
- 52 Week High
- WYHG $5.35
- ATAI $2.64
- Technical
- Relative Strength Index (RSI)
- WYHG N/A
- ATAI 42.31
- Support Level
- WYHG N/A
- ATAI $1.22
- Resistance Level
- WYHG N/A
- ATAI $1.48
- Average True Range (ATR)
- WYHG 0.00
- ATAI 0.12
- MACD
- WYHG 0.00
- ATAI -0.00
- Stochastic Oscillator
- WYHG 0.00
- ATAI 20.45
Stock Price Comparison Chart: WYHG vs ATAI
About WYHG WING YIP FOOD HOLDINGS GROUP LTD SPON ADS EACH REP 1 ORD
Wing Yip Food Holdings Group Ltd is a meat producer. The company is mainly engaged in offering ready to eat and packaged meat dishes. Its product offerings include supreme crispy sausage, fully thin sausage, Chinese sausage, Dongguan Erba sausage, yellow scorpion sausage, alcohol sausage, and meat chop.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.